A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) ± CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Paz-Ares, L. [1 ]
Balint, B. [2 ]
de Boer, R. [3 ]
van Meerbeeck, J. P. [4 ]
Wierzbicki, R. [5 ]
Desouza, P. L. [6 ]
Galimi, F.
Haddad, V. [8 ]
Hei, Y. [7 ]
Ramlau, R. [9 ]
机构：
[1] Virgen del Rocio Univ Hosp, Med Oncol Serv, Seville, Spain
[2] Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary
[3] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
[4] Univ Hosp, Dept Resp Med, Ghent, Belgium
[5] Durham Reg Canc Ctr, Oshawa, Cape Verde
[6] St George Hosp, Ctr Canc, Kogarah, NSW, Australia
[7] Amgen Inc, Oncol Therapeut, Thousand Oaks, CA 91320 USA
[8] Amgen Ltd, Cambridge, England
[9] Wielkopolskie Ctr Pulmonol & Torakochirurg, Poznan, Poland
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [1] A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Paz-Ares, Luis
    Balint, Beatrix
    de Boer, Richard H.
    van Meerbeeck, Jan P.
    Wierzbicki, Rafal
    De Souza, Paul
    Galimi, Francesco
    Haddad, Vincent
    Sabin, Tony
    Hei, Yong-jiang
    Pan, Yang
    Cottrell, Susan
    Hsu, Cheng-Pang
    RamLau, Rodryg
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 329 - 337
  • [2] Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
    Shaw, Alice T.
    Ghizdavescu, Doru
    Jain, Minish
    Volovat, Constantin
    Subramaniam, Deepa
    Shuster, Dale
    Jin, Xiaoping
    Dutta, Dipen
    Pai, Seema
    von Roemeling, Reinhard
    [J]. CANCER RESEARCH, 2012, 72
  • [3] Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Heymach, J.
    Paz-Ares, L.
    De Braud, F.
    Sebastian, M.
    Stewart, D. J.
    Eberhardt, W.
    Herbst, S.
    Krebs, A.
    Langmuir, P.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
    Lynch, T. J.
    Bondarenko, I. N.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R. T.
    Sebastian, M.
    Siegel, J.
    Cuillerot, J.
    Reck, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Okano, Yoshio
    Sakai, Mizu
    Takaoka, Masato
    Tsukuda, Tsukie
    Anabuki, Kazuki
    Kawase, Shigeo
    Miyamoto, Shintaro
    Ohnishi, Hiroshi
    Hatakeyama, Nobuo
    Machida, Hisanori
    Urata, Tomoyuki
    Yamamoto, Akira
    Ogushi, Fumitaka
    Yokoyama, Akihito
    [J]. ANTICANCER RESEARCH, 2016, 36 (01) : 307 - 312
  • [6] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Hidehito Horinouchi
    Noboru Yamamoto
    Hiroshi Nokihara
    Takeshi Horai
    Makoto Nishio
    Fumiyoshi Ohyanagi
    Atsushi Horiike
    Kazuhiko Nakagawa
    Masaaki Terashima
    Takafumi Okabe
    Hiroyasu Kaneda
    Mark D. McKee
    Dawn M. Carlson
    Hao Xiong
    Tomohide Tamura
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 37 - 43
  • [7] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Horai, Takeshi
    Nishio, Makoto
    Ohyanagi, Fumiyoshi
    Horiike, Atsushi
    Nakagawa, Kazuhiko
    Terashima, Masaaki
    Okabe, Takafumi
    Kaneda, Hiroyasu
    McKee, Mark D.
    Carlson, Dawn M.
    Xiong, Hao
    Tamura, Tomohide
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 37 - 43
  • [8] Phase II study of biweekly carboplatin and paclitaxel as first-line treatment for elderly patients with advanced non-small cell lung cancer
    Terai, H.
    Soejima, K.
    Nakamura, M.
    Naoki, K.
    Yasuda, H.
    Satomi, R.
    Nakayama, S.
    Yoda, S.
    Ikemura, S.
    Sato, T.
    Asano, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] A Phase Ii Study Of Carboplatin And Weekly Paclitaxel Combined With Bevacizumab For The First-Line Treatment Of Advanced Non-Small Cell Lung Cancer
    Kubota, T.
    Okano, Y.
    Sakai, M.
    Takaoka, M.
    Tsukuda, T.
    Anabuki, K.
    Kawase, S.
    Miyamoto, S.
    Ohnishi, H.
    Urata, T.
    Takeuchi, E.
    Ogushi, F.
    Yokoyama, A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [10] Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Sequist, L
    Fidias, P
    Temel, J
    Kennedy, E
    Ostler, P
    Rabin, M
    Huberman, M
    Keck, J
    Brown, G
    Lynch, T
    [J]. LUNG CANCER, 2005, 49 : S269 - S269
12345